EMvision Medical Devices Ltd
ASX:EMV
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.465
2.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
EMvision Medical Devices Ltd
EMvision Medical Devices Ltd
Cash & Cash Equivalents
EMvision Medical Devices Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash & Cash Equivalents
AU$18.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
R
|
Respiri Ltd
ASX:RSH
|
Cash & Cash Equivalents
AU$762.9k
|
CAGR 3-Years
-54%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-21%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Cash & Cash Equivalents
AU$24.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cash & Cash Equivalents
AU$27.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
37%
|
CAGR 10-Years
35%
|
|
|
Cochlear Ltd
ASX:COH
|
Cash & Cash Equivalents
AU$513.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
46%
|
CAGR 10-Years
25%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash & Cash Equivalents
AU$6.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
28%
|
CAGR 10-Years
56%
|
|
EMvision Medical Devices Ltd
Glance View
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company is headquartered in Brisbane, Queensland. The company went IPO on 2018-12-13. The Company’s principal activity consists of research and development of medical imaging and diagnostic technology for the purpose of commercializing portable medical device for stroke diagnosis and monitoring, as well as other medical imaging needs. The firm is engaged in developing portable brain scanner for stroke diagnosis and monitoring.
See Also
What is EMvision Medical Devices Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
18.6m
AUD
Based on the financial report for Jun 30, 2024, EMvision Medical Devices Ltd's Cash & Cash Equivalents amounts to 18.6m AUD.
What is EMvision Medical Devices Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
34%
Over the last year, the Cash & Cash Equivalents growth was 87%. The average annual Cash & Cash Equivalents growth rates for EMvision Medical Devices Ltd have been 24% over the past three years , 34% over the past five years .
You don't have any saved screeners yet
